Norgine is a European pharmaceutical company focused on creating treatments in the areas of gastroenterology, hepatology and critical care.
NER1006 is a polyethylene glycol-based bowel preparation intended to cleanse the colon before a colonoscopy.
Under the agreement, Valeant will obtain the rights to develop and commercialize the drug in the U.S. and Canada, while Norgine will serve as the company‘s manufacturer and supplier.
The companies anticipate U.S. regulatory filing for the drug by the end of 2016. Financial terms of the deal were not disclosed.
More articles on the drug market:
Merck’s blockbuster drug Keytruda approved to treat head and neck cancer
FDA approves Aurobindo’s new anti-infective
Teva’s Cephalon inked $125M settlement with 48 states over generic delays
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
